Laboratories cannot keep up with the demand for coronavirus disease 2019 (COVID-19) testing results; job losses in Texas have led to many losing their insurance; a new California poll shows that Latinos worry most about finances and getting sick from COVID-19.
Shortages of key supplies from Roche, Abbott, Cepheid, and Hologic may be to blame for the current bottleneck in testing for coronavirus disease 2019 (COVID-19) at many US laboratories, Medscape details. These public and private labs need to be running between 6 and 10 million tests per day to keep up with demand but are only able to handle close to 800,000, the article reports, which comes out to between 8% and 13.3% of the testing need being fulfilled. However, much of their automated testing equipment from these companies cannot run without parts specifically from them, and that has created a supply chain nightmare. Close to 53 million COVID-19 tests have already been performed in the United States and its territories.
As 1 of only 13 states that did not expand Medicaid coverage under the Affordable Care Act, almost 695,000 people in Texas lost their insurance when they lost their jobs from February through May, according to Kaiser Health News. The costs of COVID-19 testing, which can run in the hundreds of dollars in the state, have added even more strain to this population, 29% of whom are under the age of 65. Texas hospitals already were providing care to uninsured individuals at an annual cost of more than $7 billion, before COVID-19. The state is 1 of 23 currently seeing uncontrolled spread of the virus, although the past 2 weeks have seen new cases trend downward.
The Los Angeles Times is reporting that a recent Public Policy Institute of California poll shows that financial and mental health strain from COVID-19 have affected Latinos the most compared with Black, white, and Asian Americans who also live in the state. This can be seen in the numbers: Latinos account for close to 39% of California’s total residents and almost 40% of its essential workforce, but 55% of its COVID-19 cases. In Los Angeles County alone, their likelihood of becoming infected is twice that of white residents.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More